MedinCell S.A. (EPA:MEDCL)
France
· Delayed Price · Currency is EUR 21.54
-1.10 (-4.86%)
Mar 6, 2026, 2:32 PM CET
MedinCell Employees
MedinCell had 145 employees as of September 30, 2025. The number of employees increased by 14 or 10.69% since the number was reported on March 31, 2025.
Employees
145
Change
14
Growth
10.69%
Revenue / Employee
€223,717
Profits / Employee
€137,572
Market Cap
749.45M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 700 |
| Inventiva | 84 |
| DBV Technologies | 117 |
| Nanobiotix | 103 |
| Genfit | 188 |
| Transgene | 147 |
| Cellectis | 222 |
| Innate Pharma | 174 |
MedinCell News
- 12 days ago - Teva, Medincell granted FDA review for long-acting antipsychotic - Seeking Alpha
- 13 days ago - FDA Accepts NDA For Teva And Medincell's Olanzapine LAI In Schizophrenia Treatment - Nasdaq
- 5 months ago - Teva : FDA Grants Expanded Approval For UZEDY To Treat Bipolar I Disorder In Adults - Nasdaq
- 5 months ago - Medincell Reports Positive Phase 3 Safety Data For Olanzapine LAI; No PDSS Observed - Nasdaq
- 1 year ago - Teva Pharmaceuticals reports completion of phase 3 trial for Olanzapine LAI in Schizophrenia - Seeking Alpha